MCID: HNS001
MIFTS: 34

Hansen's Disease

Categories: Neuronal diseases, Rare diseases, Skin diseases, Smell/Taste diseases

Aliases & Classifications for Hansen's Disease

MalaCards integrated aliases for Hansen's Disease:

Name: Hansen's Disease 52 3
Leprosy 52 71

Classifications:



External Ids:

UMLS 71 C0023343

Summaries for Hansen's Disease

NIH Rare Diseases : 52 Hansen's disease (also known as leprosy) is a rare bacterial infection that affects the skin, nerves and mucous membranes . After exposure, it may take anywhere from 2 to 10 years to develop features of the condition. Once present, common signs and symptoms include skin lesions ; muscle weakness or paralysis; eye problems that may lead to blindness; nosebleeds; severe pain; and/or numbness in the hands, feet, arms and legs. Hansen's disease is caused by the bacterium Mycobacterium leprae; however, the way in which the bacterium is transmitted (spread) is poorly understood. It appears that only about 5% of people are susceptible to the condition. Hansen's disease is easily treated with combination antibiotics for 6 months to 2 years.

MalaCards based summary : Hansen's Disease, also known as leprosy, is related to leprosy 1 and leprosy 5. An important gene associated with Hansen's Disease is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Rifampicin and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells.

CDC : 3 Hansen's disease (also known as leprosy) is an infection caused by slow-growing bacteria called Mycobacterium leprae. It can affect the nerves, skin, eyes, and lining of the nose (nasal mucosa). With early diagnosis and treatment, the disease can be cured. People with Hansen's disease can continue to work and lead an active life during and after treatment. Leprosy was once feared as a highly contagious and devastating disease, but now we know it doesn't spread easily and treatment is very effective. However, if left untreated, the nerve damage can result in crippling of hands and feet, paralysis, and blindness.

Related Diseases for Hansen's Disease

Diseases related to Hansen's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 781)
# Related Disease Score Top Affiliating Genes
1 leprosy 1 12.8
2 leprosy 5 12.5
3 leprosy 2 12.5
4 leprosy 4 12.4
5 leprosy 3 12.2
6 trigeminal trophic syndrome 11.5
7 buruli ulcer 11.5
8 mycobacterium kansasii 11.5
9 chronic rhinitis 11.5
10 fetal thalidomide syndrome 11.5
11 mycobacterium abscessus 11.2
12 lepromatous leprosy 10.7
13 neuropathy 10.5
14 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
15 peripheral nervous system disease 10.4
16 tuberculoid leprosy 10.3
17 neuritis 10.3
18 autoimmune disease 10.3
19 arthritis 10.3
20 47,xyy 10.3
21 systemic lupus erythematosus 10.2
22 tetanus 10.2
23 ectropion 10.2
24 paragangliomas 1 10.2
25 scabies 10.2
26 exanthem 10.2
27 uveitis 10.2
28 glomerulonephritis 10.2
29 pulmonary tuberculosis 10.2
30 antiphospholipid syndrome 10.2
31 mycosis fungoides 10.2
32 leprosy 6 10.2
33 borderline leprosy 10.2
34 skin disease 10.2
35 yaws 10.1
36 48,xyyy 10.1
37 dysautonomia 10.1
38 crohn's disease 10.1
39 visceral leishmaniasis 10.1
40 infant gynecomastia 10.1
41 onchocerciasis 10.1
42 gynecomastia 10.1
43 hepatitis 10.1
44 tenosynovitis 10.1
45 autonomic dysfunction 10.1
46 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1
47 indeterminate leprosy 10.1
48 arthropathy 10.1
49 syphilis 10.1
50 cataract 10.1

Graphical network of the top 20 diseases related to Hansen's Disease:



Diseases related to Hansen's Disease

Symptoms & Phenotypes for Hansen's Disease

Drugs & Therapeutics for Hansen's Disease

Drugs for Hansen's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3 Cytochrome P-450 CYP3A Inducers Phase 4
4 Antibiotics, Antitubercular Phase 4
5 Antiparasitic Agents Phase 4
6 Antiprotozoal Agents Phase 4
7 Antimalarials Phase 4
8 Vitamins Phase 4
9 Vaccines Phase 4
10 Anti-Bacterial Agents Phase 4
11 Anti-Infective Agents Phase 4
12 Immunosuppressive Agents Phase 4
13 Angiogenesis Inhibitors Phase 4
14 Immunologic Factors Phase 4
15
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
16
Perphenazine Approved Phase 3 58-39-9 4748
17
Amitriptyline Approved Phase 3 50-48-6 2160
18
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
19
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
20
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
21
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
22
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181
23
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
24
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
25
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
26
Infliximab Approved Phase 3 170277-31-3
27
Clofazimine Approved, Investigational Phase 2, Phase 3 2030-63-9 2794
28
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
29
Norgestimate Approved, Investigational Phase 2, Phase 3 35189-28-7 6540478
30
Linezolid Approved, Investigational Phase 2, Phase 3 165800-03-3 441401
31
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3 50-28-2 5757
32
Polyestradiol phosphate Approved Phase 2, Phase 3 28014-46-2
33
Moxifloxacin Approved, Investigational Phase 2, Phase 3 151096-09-2, 354812-41-2 152946
34
Ethinyl Estradiol Approved Phase 2, Phase 3 57-63-6 5991
35
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
36 Tocotrienol Investigational Phase 3 6829-55-6
37 Antipsychotic Agents Phase 3
38 Tranquilizing Agents Phase 3
39 Narcotics Phase 3
40 Psychotropic Drugs Phase 3
41 Analgesics, Opioid Phase 3
42 Analgesics, Non-Narcotic Phase 3
43 Antidepressive Agents Phase 3
44 Analgesics Phase 3
45 Central Nervous System Depressants Phase 3
46 Amitriptyline, perphenazine drug combination Phase 3
47 Adrenergic Agents Phase 3
48 Antidepressive Agents, Tricyclic Phase 3
49 Cyclosporins Phase 2, Phase 3
50 Antifungal Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
3 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
4 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
5 Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L:A Multi-center Randomized Controlled Trial Recruiting NCT03519568 Phase 4
6 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
7 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Unknown status NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
8 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
9 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
10 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
11 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
12 Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection) Completed NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
13 A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
14 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
15 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
16 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
17 Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
18 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Not yet recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
19 Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD) Not yet recruiting NCT04081077 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine
20 To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus. Unknown status NCT02023411 Phase 2 Teriparatide
21 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
22 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
23 Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00162760 Phase 2 Thalidomide
24 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
25 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
26 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
27 A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas Completed NCT00047879 Phase 2 Thalidomide
28 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
29 Efficacy and Safety of Low Dose Thalidomide in Thalassemia Intermedia Patients of Pakistan Recruiting NCT03651102 Phase 2 Thalidomide Oral Product
30 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
31 Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease Recruiting NCT02968212 Phase 2 Clofazimine
32 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Not yet recruiting NCT03947437 Phase 1, Phase 2
33 A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis. Terminated NCT00469703 Phase 2 Thalidomide
34 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
35 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Terminated NCT03341767 Phase 2 Clofazimine;Placebo
36 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
37 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
38 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
39 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
40 Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses Completed NCT02493283 Phase 1 Dapsone single dose;Dapsone multiple dose
41 A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG. Completed NCT00654316 Phase 1
42 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
43 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis. Completed NCT00456183 Phase 1
44 A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV Completed NCT00395720 Phase 1
45 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
46 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
47 Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer. Unknown status NCT01751503
48 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
49 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
50 Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial Completed NCT00860717

Search NIH Clinical Center for Hansen's Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide

Genetic Tests for Hansen's Disease

Anatomical Context for Hansen's Disease

MalaCards organs/tissues related to Hansen's Disease:

40
Skin, Testes, T Cells, Eye, Bone, Liver, Monocytes

Publications for Hansen's Disease

Articles related to Hansen's Disease:

(show top 50) (show all 20603)
# Title Authors PMID Year
1
Clinicodermoscopic study of histoid leprosy: a case series. 61
31769010 2020
2
Sarcoidosis with Cutaneous Perineural Granulomas and Neurological Manifestations: A Potential Mimicker of Leprosy. 61
32022940 2020
3
Proposing BCG Vaccination for Mycobacterium avium ss. paratuberculosis (MAP) Associated Autoimmune Diseases. 61
32033287 2020
4
A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults. 61
31899025 2020
5
A distinct double positive IL-17A+/F+ T helper 17 cells induced inflammation leads to IL17 producing neutrophils in Type 1 reaction of leprosy patients. 61
31629113 2020
6
Erythema Nodosum Leprosum Neutrophil Subset Expressing IL-10R1 Transmigrates into Skin Lesions and Responds to IL-10. 61
32034084 2020
7
"Buruli ulcer and leprosy, they are intertwined": Patient experiences of integrated case management of skin neglected tropical diseases in Liberia. 61
32023242 2020
8
Efficacy of Topical Insulin Therapy for Chronic Trophic Ulcers in Patients with Leprosy: A Randomized Interventional Pilot Study. 61
31972587 2020
9
Hot spots of leprosy in the endemic area of São Luís, Maranhão State, Northeastern Brazil. 61
31501023 2020
10
Letter to editor in response to the article 'Position statement: LEPROSY: diagnosis, treatment and follow-up'. 61
31505055 2020
11
The Importance of the Biopsy Technique in the Diagnosis of Histoid Leprosy. 61
31268927 2020
12
Leprosy in the North and Northeast regions of Brazil: an integrated spatiotemporal approach. 61
31713982 2020
13
Nursing in a Community With Leprosy at the Center: A Conversation With Remi Kalnime. 61
32024736 2020
14
Case Report: Nasal Myiasis in an Elderly Patient with Atrophic Rhinitis and Facial Sequelae of Leprosy. 61
31802737 2020
15
A case of diffuse lepromatous leprosy with Lucio phenomenon. 61
31198950 2020
16
Scoping review: Community-based programmes with people affected by leprosy. 61
31713954 2020
17
Community health care workers in pursuit of TB: Discourses and dilemmas. 61
31954279 2020
18
A systematic review on Piper longum L.: Bridging traditional knowledge and pharmacological evidence for future translational research. 61
31568819 2020
19
Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats. 61
31915967 2020
20
The potential role of interleukin-37 in infectious diseases. 61
31633447 2020
21
BCG: a vaccine with multiple faces. 61
31995448 2020
22
Causes of Death among Persons Affected by Leprosy in Korea, 2010-2013. 61
31769407 2020
23
Update on the use of dapsone in dermatology. 61
31909480 2020
24
A Quality of Life Study of Patients with Leprosy Attending the Dermatology OPD of a Tertiary Care Center of Eastern India. 61
32029939 2020
25
Leprosy in urban space, areas of risk for disability and worsening of this health condition in Foz Do Iguaçu, the border region between Brazil, Paraguay and Argentina. 61
31996183 2020
26
Commingled crypts: Comparative health among Byzantine monastics in the Levant. 61
31907930 2020
27
FAMIN Is a Multifunctional Purine Enzyme Enabling the Purine Nucleotide Cycle. 61
31978345 2020
28
Women from the Federation of Societies for the Care of Lepers and Defense Against Leprosy, 1926-1947. 61
31994681 2020
29
World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis. 61
31959113 2020
30
Leprosy reactions in North-East Mexico: epidemiology and risk factors for chronic erythema nodosum leprosum. 61
31944428 2020
31
Utility and limitations of serodiagnostic tests in monitoring the response to treatment of leprosy patients. 61
31954594 2020
32
A critical comparative ethnographic study of courtesy stigma in two leprosy-impacted communities in Indonesia. 61
31971879 2020
33
Leprosy in French Guiana 2007-2014: a re-emerging public health problem. 61
31286485 2020
34
Type 2 leprosy reaction resembling Sweet syndrome: Review of new and published cases. 61
31984474 2020
35
Patients help other patients: Qualitative study on a longstanding community cooperative to tackle leprosy in India. 61
31929530 2020
36
Novel PCR primers for improved detection of Mycobacterium leprae and diagnosis of leprosy. 61
31981442 2020
37
Effectiveness and safety of autologous platelet-rich plasma therapy with total contact casting versus total contact casting alone in treatment of trophic ulcer in leprosy: An observer-blind, randomized controlled trial. 61
31997794 2020
38
Evidence for Mycobacterium leprae Drug Resistance in a Large Cohort of Leprous Neuropathy Patients from India. 61
31933458 2020
39
Myelin breakdown favours Mycobacterium leprae survival in Schwann cells. 61
31652371 2020
40
Reply to: Single-dose rifampicin and BCG to prevent leprosy. 61
32014601 2020
41
Single-dose rifampicin and BCG to prevent leprosy. 61
32014603 2020
42
Leprosy elimination - Still a long way to go. 61
31939491 2020
43
Prevention of transmission of leprosy: The current scenario. 61
31975697 2020
44
18F-FDG PET/CT Imaging Findings of Leprosy. 61
31977489 2020
45
Tuberculoid leprosy: An in vivo microvascular evaluation of cutaneous lesions. 61
31929590 2020
46
Leprosy pseudoimbricata: an unusual presentation of steroid-modified borderline lepromatous leprosy. 61
31957882 2020
47
Schwann cells as underestimated, major players in human skin physiology and pathology. 61
31733169 2020
48
Indian Sarsaparilla (Hemidesmus indicus): Recent progress in research on ethnobotany, phytochemistry and pharmacology. 61
32007632 2020
49
Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics. 61
31392755 2020
50
Rapidly progressive glomerulonephritis (RPGN) in Hansen's disease. 61
31979739 2020

Variations for Hansen's Disease

Expression for Hansen's Disease

Search GEO for disease gene expression data for Hansen's Disease.

Pathways for Hansen's Disease

GO Terms for Hansen's Disease

Sources for Hansen's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....